Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.
about
Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts.Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update.Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia.
P2860
Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.
@en
type
label
Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.
@en
prefLabel
Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.
@en
P2860
P356
P1433
P1476
Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia
@en
P2093
Jordan Baye
Matthew A Cantrell
P2860
P304
P356
10.1002/PHAR.1243
P407
P577
2013-03-25T00:00:00Z